Kura Oncology (KURA) Return on Equity (ROE)

Price: $6.52
Market Cap: $526.52M
Avg Volume: 1.46M
Country: US
Industry: Biotechnology
Sector: Healthcare
Beta: 0.843
52W Range: $6.27-23.48
Website: Kura Oncology

Return on Equity (ROE) Summary

Kura Oncology's ROE measures the return generated on shareholders' equity:

  • Annual: -42.06%
  • Quarterly: -4.65%
  • TTM: -38.48%

What is Return on Equity (ROE)?

Return on Equity measures a company's ability to generate profits from its shareholders' equity. It indicates how effectively the management is using the company’s assets to create profits. A higher ROE generally reflects well on the company’s management and its ability to generate profits without needing as much capital.

Related Metrics

Other important metrics to assess Kura Oncology's profitability include:

  • ROIC (Return on Invested Capital) - measures how effectively the company uses its invested capital to generate profits:
    • Annual: -28.42%
    • Quarterly: 0.00%
    • TTM: -25.21%
  • ROA (Return on Assets) - measures the return generated on the company's assets:
    • Annual: -22.89%
    • Quarterly: -2.53%
    • TTM: -22.89%
  • Profit Margin - indicates the profitability of the company relative to its revenue:
    • Annual: -322.89%
    • Quarterly: -35.66%
    • TTM: -322.89%

These metrics provide insights into Kura Oncology's profitability and efficiency in using its capital and assets to generate returns. Comparing these ratios with industry benchmarks can offer a deeper understanding of the company's performance.

Annual ROE

-42.06%

Quarterly ROE

-4.65%

TTM ROE

-38.48%

Kura Oncology Historical ROE
58.13%58.13%40.37%40.37%22.60%22.60%4.84%4.84%-12.93%-12.93%-30.69%-30.69%-48.46%-48.46%ROE20162016201720172018201820192019202020202021202120222022202320232024202420252025
Historical ROIC
0.00%0.00%-8.80%-8.80%-17.61%-17.61%-26.41%-26.41%-35.22%-35.22%-44.02%-44.02%ROIC20162016201720172018201820192019202020202021202120222022202320232024202420252025
Historical ROA
7.89%7.89%-0.00%-0.00%-7.89%-7.89%-15.79%-15.79%-23.68%-23.68%-31.58%-31.58%-39.47%-39.47%ROA20162016201720172018201820192019202020202021202120222022202320232024202420252025

Kura Oncology Historical Profitability Metrics

The table below shows various profitability metrics for each year, with the latest data available for the last fiscal year 2024.

Year ROE ROIC ROA Profit Margin
2024 -42.06% -28.42% -22.89% -322.89%
2023 -38.42% -39.94% -34.00% 0.00%
2022 23.92% -32.24% -29.82% 0.00%
2021 30.00% -25.54% -24.33% 0.00%
2020 29.56% -14.67% -13.82% 0.00%
2019 29.66% -29.74% -26.09% 0.00%
2018 40.37% -39.36% -33.14% 0.00%
2017 -44.37% -41.27% -36.97% 0.00%
2016 -48.46% -44.02% -39.47% 0.00%
2015 -27.56% -29.01% -25.93% 0.00%

Related Metrics

Explore detailed financial metrics and analysis for KURA.

Financial Analysis
Financial Statements Stock Forecast Price Target Technical Analysis Stock Splits Employee Count
Company Intelligence
Ownership Insider Trading SEC Filings Congress Trading News Earnings Call Transcripts
Income & Revenue
Earnings Revenue Revenue Growth Profit Net Income Profit Margin EBITDA Free Cash Flow Revenue Segments
Valuation
Valuation Market Cap Enterprise Value P/E Ratio PEG Ratio P/S Ratio P/B Ratio Book Value
Returns & Ratios
ROIC ROE ROA Current Ratio Quick Ratio Debt/Equity Ratio Earnings Per Share
Balance Sheet
Assets Debt Cash On Hand Shares Outstanding
Dividends
Dividends Dividend Yield Payout Ratio